global
pandem
coronaviru
diseas
disast
human
societi
conveni
reliabl
vitro
neutral
assay
import
develop
neutral
antibodi
vaccin
inhibitor
studi
g
proteindefici
vesicular
stomat
viru
vsvdg
bear
fulllength
truncat
spike
protein
evalu
viru
packag
effici
ctermin
amino
acid
truncat
much
higher
neutral
assay
antibodi
screen
serum
neutral
titer
quantif
establish
base
pseudoviru
human
angiotensinconvert
enzym
overexpress
cell
experiment
result
obtain
automat
count
egfp
posit
cell
number
hour
infect
make
assay
conveni
highthroughput
serum
neutral
titer
convalesc
patient
measur
pseudoviru
assay
good
correl
live
assay
seven
neutral
monoclon
antibodi
target
receptor
bind
domain
rbd
obtain
effici
reliabl
pseudoviru
assay
model
could
facilit
develop
new
drug
vaccin
april
million
case
coronaviru
diseas
report
includ
death
spread
viru
difficult
control
due
highli
contagi
asymptomat
infect
urgent
need
develop
vaccin
therapeut
infect
howev
cultur
assay
need
carri
biosafeti
laboratori
limit
effici
research
develop
r
wide
avail
conveni
function
assay
cellbas
assay
neutral
quantif
essenti
vaccin
therapeut
antibodi
r
belong
genu
betacoronaviru
envelop
glycosyl
spike
protein
major
surfac
protein
respons
receptor
bind
fusion
viral
membran
cellular
membran
studi
show
sarscov
bind
receptor
human
angiotensinconvert
enzym
similar
affin
therefor
studi
sarscov
neutral
assay
base
pseudoviru
bear
spike
protein
sarscov
would
provid
valuabl
experi
refer
assay
past
year
pseudotyp
system
base
vesicular
stomat
viru
vsv
report
produc
pseudotyp
incorpor
envelop
protein
heterolog
risk
group
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
coronaviru
et
al
vsv
g
gene
delet
vsvdg
gene
encod
gfp
luciferas
report
gene
integr
pseudotyp
virus
provid
safe
viral
entri
model
inabl
produc
infecti
progeni
viru
vsv
assembl
occur
plasma
membran
involv
bud
virion
cell
surfac
bud
vsv
acquir
envelop
consist
lipid
bilay
deriv
plasma
membran
spike
protein
consist
trimer
vsv
glycoprotein
vsvg
vsvg
absenc
glycoprotein
heterolog
viru
complac
express
cell
infect
rvsvdg
glycoprotein
heterolog
viru
could
assembl
vsv
membran
recent
michael
letko
et
al
use
vsvdgluc
bear
sarsspik
chimera
studi
cell
entri
receptor
usag
lineag
b
betacoronavirus
jianhui
nie
et
al
success
construct
pseudoviru
neutral
assay
consist
pseudotyp
vsv
bear
fulllength
spike
protein
cell
lentivir
pseudotyp
bear
truncat
spike
protein
also
construct
use
studi
viru
entri
immun
crossreact
sarscov
noteworthi
correl
pseudoviru
system
live
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
viru
system
nt
verifi
viru
packag
infect
effici
also
one
limit
factor
highthroughput
vitro
neutral
assay
report
pseudotyp
vsv
retroviru
bear
sarscov
protein
variant
truncat
cytoplasm
tail
much
higher
infect
effici
fulllength
protein
studi
vsvdg
pseudotyp
fulllength
protein
truncat
protein
ctermin
aa
truncat
compar
found
infect
effici
much
higher
among
cell
line
use
studi
stabli
express
human
sensit
infect
suitabl
viru
packag
neutral
assay
antibodi
screen
valid
establish
base
cell
strain
neutral
monoclon
antibodi
target
receptor
bind
domain
rbd
obtain
importantli
correl
pseudoviru
system
live
viru
system
verifi
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
han
cell
maintain
high
glucos
dmem
sigmaaldrich
supplement
fb
gibco
penicillin
iuml
streptomycin
environ
passag
everi
day
construct
vsv
pseudoviru
carri
spike
protein
spike
gene
strain
genbank
codonoptim
express
human
cell
clone
eukaryot
express
plasmid
pcag
gener
recombin
plasmid
pcagncov
spike
gene
mutant
ctermin
aa
truncat
also
clone
plasmid
pcag
gener
plasmid
pcagncov
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
transfect
respect
hour
post
transfect
vsvdgegfpg
addgen
viru
inocul
cell
express
spike
protein
truncat
protein
incub
one
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
analyz
columbu
system
perkinelm
number
gfpactiv
cell
well
count
repres
infect
perform
reduct
mab
treatment
gfpactiv
cell
number
compar
nontreat
control
well
calcul
show
neutral
potenc
inhibit
rate
mab
serum
calcul
accord
decreas
gfp
posit
cell
number
pseudotypebas
neutral
assay
decreas
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
rna
level
live
neutral
assay
half
maxim
inhibitori
concentr
id
plasmaserum
dilut
caus
reduct
gfpposit
cell
number
rna
level
valu
calcul
nonlinear
regress
ie
log
inhibitor
vs
normal
respons
variabl
slope
use
graphpad
prism
graphpad
softwar
inc
san
diego
ca
usa
correl
analysi
result
pseudoviru
system
live
viru
system
analys
linear
regress
use
graphpad
prism
compar
infect
effici
pseudotyp
bear
differ
glycosyl
protein
singl
cycl
infecti
recombin
vsvdgegfpg
prepar
use
infect
cell
transient
express
fulllength
protein
truncat
protein
ctermin
aa
truncat
respect
pseudotyp
obtain
follow
procedur
describ
method
figur
cell
seed
compar
infect
effici
pseudotyp
infect
effici
vsv
pseudotyp
bear
truncat
much
higher
fulllength
protein
result
suggest
combin
cell
could
better
altern
establish
pseudotyp
entri
neutral
assay
viral
packag
effici
one
limit
factor
highthroughput
vitro
neutral
assay
select
cell
line
appropri
pseudotyp
product
compar
viral
titer
packag
cell
result
show
form
syncytia
two
cell
line
packag
also
produc
highest
viral
titer
figur
infecti
particl
per
minilit
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
determin
optim
incub
period
detect
infect
timecours
monitor
egfp
express
perform
use
opera
phenix
high
content
screen
system
egfp
express
could
detect
earli
hour
post
infect
number
gfpposit
cell
gradual
increas
reach
plateau
phase
within
hour
remain
stabl
hour
figur
wherea
fluoresc
intens
increas
continu
pseudovirus
unabl
produc
progeni
virus
infect
cell
number
would
better
indic
infect
effici
therefor
infect
effici
could
quantit
evalu
hour
count
number
gfpposit
cell
firstli
test
respons
also
mean
pseudovirus
system
mimic
entri
live
viru
system
use
highthroughput
screen
neutral
antibodi
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
shown
figur
strain
mous
monoclon
antibodi
hybridoma
cultur
supernat
evalu
use
pseudoviru
system
show
signific
neutral
select
neutral
antibodi
antivir
activ
also
analyz
figur
use
pseudoviru
system
base
system
use
analyz
neutral
antibodi
serum
convalesc
patient
serum
dilut
first
concentr
prepar
doubl
dilut
etc
cell
seed
incub
mixtur
gradient
dilut
serum
viru
gfp
posit
cell
number
count
analys
neutral
activ
serum
figur
among
test
sera
show
high
neutral
activ
id
similar
assay
also
perform
use
live
system
sera
show
high
neutral
activ
id
accord
live
viru
assay
figur
analysi
result
pseudoviru
system
correl
well
live
viru
system
r
p
figur
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
epidem
spread
rapidli
around
world
urgent
need
vaccin
therapeut
drug
isol
cultur
handl
biosafeti
level
facil
limit
research
develop
drug
safer
effici
assay
drug
evalu
would
acceler
develop
drug
pseudoviru
system
provid
conveni
tool
research
virus
make
evalu
inhibitor
viral
entri
neutral
antibodi
immunizedserum
much
easier
retroviru
vsv
common
use
pseudoviru
system
pseudotyp
viru
titer
obtain
vsvdg
system
gener
higher
retroviru
system
furthermor
infect
cell
report
gene
firefli
luciferas
use
indic
infect
pseudotyp
viru
noteworthi
truncat
cytoplasm
tail
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
may
increas
fusion
activ
consist
studi
sivmulv
chimer
envelop
protein
enhanc
syncytia
aris
fusion
may
contribut
improv
packag
effici
pseudotyp
vsv
c
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
h
post
infect
calcul
inhibit
ratio
analys
nonlinear
regress
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
figur
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
figur
ccbyncnd
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
